PRESS CONFERENCE SCHEDULE
Conference on Retroviruses and Opportunistic Infections/CROI 2020

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study’s presentation at the conference or at the end of the panel on which it is presented in a CROI press conference, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/650180197 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 650-180-197; International telephone access numbers here. Playback available on the CROI conference website.

Sunday, March 8, 3:30 – 4:40 pm

3:30 – 3:50 pm  Chaired by Sharon Hillier, CROI Chair and University of Pittsburgh, Pittsburgh, PA, US

WELCOME AND OVERVIEW OF CROI 2020
Sharon Hillier, CROI Chair and University of Pittsburgh, Pittsburgh, PA, US
Elaine Abrams, CROI Vice Chair and Columbia University, New York, NY, US
James Hoxie, University of Pennsylvania, Philadelphia, PA, US

3:50 – 4:15 PM  Chaired by Wafaa El-Sadr, ICAP at Columbia University, New York, NY, US
(EMBARGO ON THESE STUDIES LIFTS SUNDAY, MARCH 8, 4:15 PM ET)

ORAL ABSTRACT SESSION 4 – COMMUNITY AND CLINIC-BASED HIV TREATMENT, PREVENTION INTERVENTIONS, AND INSIGHTS
(PRESENTED MONDAY, MARCH 9 10:00 AM - 12:00 PM)

47. Population-Level Viremia Predicts HIV Incidence Across Universal Test & Treat Studies
Maya Petersen, University of California, Berkeley, Berkeley, CA, US

48. Decreasing Community Viremia is Associated with Decreasing HIV Incidence in Australia
Denton Callander, UNSW Sydney, Sydney, Australia

(PRESENTED WEDNESDAY, MARCH 11 10:00 AM - 12:00 PM)

145. No HIV Incidence Increase in First-Time Blood Donors with 12-Month Deferral for MSM
Eduard Grebe, Vitalant Research Institute, San Francisco, CA, US

147. Explosive HIV and HCV Epidemics Driven by Network Viremia Among PWID
Sunil Solomon, Johns Hopkins University School of Medicine, Baltimore, MD, US

151. Increased Overall Life Expectancy But Not Comorbidity-Free Years for People with HIV
Julia Marcus, Harvard Medical School, Boston, MA, US
4:15 – 4:40 PM Chaired by Kevin De Cock, CDC, Nairobi, Kenya
(EMBARGO ON THESE STUDIES LIFTS SUNDAY, MARCH 8, 4:40 PM ET)

(PRESENTED WEDNESDAY, MARCH 11 10:00 AM - 12:00 PM)

148. The Aging of HIV-1 Incidence in Hyperendemic Rural South Africa
Adam Akullian, Institute for Disease Modeling, Bellevue, WA, US

150. Rapidly Declining HIV Incidence Among Men and Women in Rakai, Uganda
Mary Grabowski, Johns Hopkins School of Medicine, Baltimore, MD, US

ORAL ABSTRACT SESSION 8 – PREVENTION 2020: AGENTS, OPTIONS, AND OUTCOMES
(PRESENTED TUESDAY, MARCH 10 10:00 AM - 12:00 PM)

94. PEPFAR DREAMS Intervention Among Adolescent Girls and Young Women in Rakai, Uganda
Hadijja Nakawooya, Rakai Health Sciences Program, Kalisizo Town, Uganda
## PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2020

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study’s presentation at the conference or at the end of the panel on which it is presented in a CROI press conference, whichever is earlier. All times listed are ET.

This press conference may be viewed live at [https://zoom.us/j/336141587](https://zoom.us/j/336141587) or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 336-141-587; Intl. telephone access numbers [here](#). Playback available on the CROI conference website.

### Monday, March 9, 12:15 – 1:15 pm

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
**Oral Abstract Session 03 – Therapeutic Interventions for HIV Treatment and Eradication**  
(Presented Monday, March 9 10:00 AM – 12:00 PM)  
34. Cabotegravir + Rilpivirine Every 2 Months is Noninferior to Monthly: ATLAS-2M Study  
Edgar Overton, University of Alabama, Birmingham, AL, US  
38. A Randomized Trial of the Impact of 3BNC117 and Romidepsin on the HIV-1 Reservoir  
Ole Søgaard, Aarhus University Hospital, Aarhus N, Denmark  
40. Safety and Analytic Treatment Interruption Outcomes of Vesatolimod in HIV Controllers  
Devi Sengupta, Gilead Sciences, Foster City, CA, US  
41LB. Durable HIV-1 Antibody Production in Humans after AAV8-Mediated Gene Transfer  
Joseph Casazza, National Institutes of Health, Bethesda, MD, US |
| 12:35 – 12:55 PM | Chaired by Judith Currier, University of California Los Angeles, CA, US  
(Embargo on these studies lifts Monday, March 9, 12:55 PM ET)  
**Themed Discussion Session 02 – Hearts and Hormones**  
(Presented Monday, March 9 1:30 - 2:30 PM)  
642. Testosterone Therapy and Subclinical Atherosclerosis Progression Among Men with HIV  
Sabina Haberlen, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US  
643. Postdischarge Outcomes Following Acute Coronary Syndrome in HIV  
Monica Parks, University of California San Francisco, CA, US  
644. Insomnia and Risk of Incident Myocardial Infarction Among People Living with HIV  
Bridget Whitney, University of Washington, Seattle, WA, US  
645. Hormone Use and HIV Alter Cardiovascular Biomarker Profiles in Transgender Women  
Jordan Lake, University of Texas Health Science Center Houston, TX, US |
12:55 – 1:15 pm

Chaired by Susan Buchbinder, *University of California San Francisco, CA, US*

(EMBARGO ON THESE STUDIES LIFTS MONDAY, MARCH 9, 1:15 PM ET)

**POSTER ABSTRACT SESSION S-01 – PREP EFFECTIVENESS**

(PRESENTED MONDAY, MARCH 9 2:30 - 4:00 PM)

980LB. TFV-DP in DBS for Pregnant/Postpartum Adolescent and Young Women on PrEP in Africa

Peter Anderson, *University of Colorado Anschutz Medical Campus, Aurora, CO, US*

**POSTER ABSTRACT SESSION S-03 – THE PROBLEM OF PERSISTENCE IN PrEP**

(PRESENTED MONDAY, MARCH 9 2:30 - 4:00 PM)


Kenneth Mayer, *Fenway Health, Boston, MA, US*

**POSTER ABSTRACT SESSION P-U04 – VIRAL SUPPRESSION, ADHERENCE, AND MORE**

(PRESENTED MONDAY, MARCH 9 2:30 - 4:00 PM)

1089LB. F/TAF vs. F/TDF for PrEP: How Much is “Better” Worth?

Rochelle Walensky, *Massachusetts General Hospital, Boston, MA, US*
PRESS CONFERENCE SCHEDULE

Conference on Retroviruses and Opportunistic Infections/CROI 2020

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study’s presentation at the conference or at the end of the panel on which it is presented in a CROI press conference, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/870424060 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 870-424-060; International telephone access numbers here. Playback available on the CROI conference website.

Tuesday, March 10, 7:30 – 8:30 am

7:30– 7:50 AM
Chaired by Sharon Hillier, University of Pittsburgh, PA, US
(EMBARGO ON THESE STUDIES LIFTS TUESDAY, MARCH 10, 7:50 AM ET)

ORAL ABSTRACT SESSION 08 – PREVENTION 2020: AGENTS, OPTIONS, AND OUTCOMES
(PRESENTED TUESDAY, MARCH 10 10:00 AM – 12:00 PM)

87. BIC/FTC/TAF Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection
Elena Bekerman, Gilead Sciences, Foster City, CA, US

88. On-Demand HIV Postexposure Prophylaxis by TAF/EVG Vaginal Inserts in Macaques
Charles Dobard, Centers for Disease Control and Prevention, Atlanta, GA, US

89LB. Weekly Oral Islatravir Provides Effective PEP Against IV Challenge with SIVMAC251
Jay Grobler, Merck & Co., West Point, PA, US

7:50– 8:30 AM
Chaired by Joseph Eron, University of North Carolina at Chapel Hill, NC, US
(EMBARGO ON THESE STUDIES LIFTS TUESDAY, MARCH 10, 8:30 AM ET)

ORAL ABSTRACT SESSION 06 – TARGETING THE PERSISTENT HIV RESERVOIR
(PRESENTED TUESDAY, MARCH 10 10:00 AM – 12:00 PM)

78LB. Combined Active and Passive Immunization in SHIV-Infected Rhesus Monkeys
Dan Barouch, Beth Israel Deaconess Medical Center, Boston, MA, US

POSTER ABSTRACT SESSION P-E06 – CURE STRATEGIES: HUMANS AND ANIMAL STUDIES
(PRESENTED TUESDAY, MARCH 10 2:30 – 4:00 PM)

345LB. PGT121 and Vesatolimod in Chronically Treated SHIV-Infected Rhesus Monkeys
Joseph Nkolola, Beth Israel Deaconess Medical Center, Boston, MA, US

346LB. Sustained HIV Remission in the London Patient: The Case for HIV Cure
Ravindra Gupta, University of Cambridge, Cambridge, UK

347LB. Sustained Remission in a 4-Year-Old HIV-Infected Child Treated in First Year of Life
Glora Heresi, University of Texas McGovern Medical School, Houston, TX, US
348LB. CCR5Δ32 SCT-Induced HIV Remission: Traces of HIV DNA But Fading Immune Reactivity
Bjoern-Erik Jensen, Duesseldorf University Hospital, Duesseldorf, Germany

ORAL ABSTRACT SESSION 05 – HIV-ASSOCIATED MALIGNANCIES AND TUMOR VIRUSES: AN EXPANDING LANDSCAPE
(PRESENTED TUESDAY, MARCH 10 10:00 AM – 12:00 PM)

70. Clearance of HPV Anal High-Grade Intraepithelial Lesions with Low-Dose Pomalidomide
Mark Polizzotto, The Kirby Institute, UNSW Sydney, Australia

MEDIA ROUNDTABLE
Tuesday, March 10, 7:00 – 7:45 pm

7:00–7:45 PM
Chaired by Susan Buchbinder, University of California San Francisco, CA, US
Richard Koup, U.S. National Institutes of Health, Bethesda, MD, US

SPECIAL SESSION: UPDATE FROM THE HVTN 702 (UHAMBO) HIV VACCINE TRIAL
Lawrence Corey, HVTN 702 Principal Investigator, Fred Hutchinson Cancer Research Center, Seattle, WA, US
Glenda Gray, HVTN 702 Protocol Chair, University of the Witwatersrand, Johannesburg, South Africa
Steven Wakefield, Fred Hutchinson Cancer Research Center, Seattle, WA, US
Ntando Yola, Desmond Tutu HIV Foundation, Cape Town, South Africa

THEMED DISCUSSION SESSION 11 – THE ROAD TO A BETTER VACCINE: CLINICAL TRIALS AND COHORT STUDIES
(PRESENTED WEDNESDAY, MARCH 11, 1:30 - 2:30 PM)
(EMBARGO ON THESE STUDIES LIFTS TUESDAY, MARCH 10, 7:45 PM ET)

288. Phase 1/2A Trial of HIV Clade C DNA with MF59- or AS01B-Adjuvanted Clade C Protein
Nigel Garrett, CAPRISA, Durban, South Africa

289. Mucosal T and B Cell Responses Induced by ALVAC-HIV/AIDSVAX-HIV B/E Late Boost Strategies
Alexandra Schuetz, US Military HIV Research Program, Bangkok, Thailand

Subject to change
PRESS CONFERENCE SCHEDULE
Conference on Retroviruses and Opportunistic Infections/CROI 2020

All press conferences will be held in room 210 of the Hynes Convention Center. Embargoes on research presented in CROI press conferences lift at the end of the study’s presentation at the conference or at the end of the panel on which it is presented in a CROI press conference, whichever is earlier. All times listed are ET.

This press conference may be viewed live at https://zoom.us/j/691630335 or accessed by phone toll-free from the U.S. at 877-853-5247 or 877-369-0926; Webinar ID: 691-630-335; International telephone access numbers here. Playback available on the CROI conference website.

Wednesday, March 11, 12:15 – 1:15 pm

12:15– 12:35 PM Chaired by David Thomas, Johns Hopkins School of Medicine, Baltimore, MD, US

**ORAL ABSTRACT SESSION 10 – GONE BUT NOT FORGOTTEN: HCV AFTER DIRECT-ACTING ANTIVIRAL THERAPY**
(PRESENTED WEDNESDAY, MARCH 11 10:00 AM – 12:00 PM)

122. Individual and Population-Impact of HCV Treatment Among People Who Inject Drugs
Javier Cepeda, University of California San Diego, La Jolla, CA, US

123LB. Large HIV Outbreak Among People who Inject Drugs, West Virginia, 2018-2019
Robert McClung, Centers for Disease Control and Prevention, Atlanta, GA, US

125. Newborn Testing Reveals High HCV Seroprevalence in Pregnant Women from New York State
Linda Styer, New York State Department of Health, Albany, NY, US

12:35– 12:55 PM Chaired by Elaine Abrams, Columbia University, New York, NY, US

**ORAL ABSTRACT SESSION 11 – CRITICAL ISSUES IN MATERNAL AND CHILD HEALTH**
(PRESENTED WEDNESDAY, MARCH 11 10:00 AM – 12:00 PM)

129. Dolutegravir-Containing ART Does Not Reduce Etonogestrel Implant Concentrations
Rena Patel, University of Washington, Seattle, WA, US

130LB. Safety and Efficacy of DTG vs. EFV and TDF vs. TAF in Pregnancy: IMPAACT 2010 Trial
Lameck Chinula, University of North Carolina Project-Malawi, Lilongwe, Malawi

133. A Randomized Trial of Point-of-Care Early Infant Diagnosis in Zambia
Carla Chibwesha, University of North Carolina Chapel Hill, NC, US

134LB. Population-Level HIV-Free Infant Survival in the SEARCH Trial
Theodore Ruel, University of California, San Francisco, CA, US
12:55–1:15 PM  Chaired by Constance Benson, University of California at San Diego, CA, US

**ORAL ABSTRACT SESSION 12 – TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HIV TESTING**
(PRESENTED WEDNESDAY, MARCH 11 10:00 AM – 12:00 PM)

138. Isoniazid to Prevent MTB Infection in HIV-Exposed Uninfected Infants  
Sylvia LaCourse, University of Washington, Seattle, WA, US

143LB. Effectiveness of 3HP Annually vs. Once for HIV-Positive People: TheWHIP3TB Trial  
Gavin Churchyard, Aurum Institute, Johannesburg, South Africa

144LB. Rifapentine Pharmacokinetics and Safety in Pregnant Women with and without HIV on 3HP  
Jyoti Mathad, Weill Cornell Medicine, New York, NY, US